6533b86dfe1ef96bd12c94d0

RESEARCH PRODUCT

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group.

Sergio RojasLihteh WuSilvio LujanManuel Díaz-llopisMauricio MaiaJ. Fernando ArevaloAndres F. LasaveDhariana AconMartin SerranoArturo AlezzandriniMaria H. BerrocalRoberto Gallego-pinazo

subject

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drug

description

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number of IVB injections per eye was 10.9 ± 6.4. At 5 years, the BCVA decreased from 20/150 (logMAR 0.9 ± 0.6) at baseline to 20/250 (logMAR 1.1 ± 0.7) (P =0.0001). The mean CMT decreased from 343.1+ 122.3 μm at baseline to 314.7 ± 128.8 μm at 60 months of follow-up (P = 0.009). Geographic atrophy (GA) was observed at baseline in 47 (16%) of 292 eyes. By 5 years, GA developed or progressed in 124 (42.5%) of 292 eyes (P0.0001).The early visual gains obtained from IVB were not maintained at 5 years of follow-up. In addition, IVB may play a role in the development or progression of GA.

yearjournalcountryeditionlanguage
2016-05-01Retina (Philadelphia, Pa.)
10.1097/iae.0000000000000827https://pubmed.ncbi.nlm.nih.gov/26529555